Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 155-160

  Yukita, Ayako ^a   Asano, Makoto ^a   Okamoto, Tomomitsu ^b   Mizutani, Shigehiko ^b   Suzuki, Hideo ^a  

^a Base Technology Center   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MONOCLONAL ANTIBODY MV833; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; ASCITES FLUID; CANCER MORTALITY; CANCER TRANSPLANTATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIFESPAN; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ASCITES; CAPILLARY PERMEABILITY; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HEMORRHAGE; HUMANS; LYMPHOKINES; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECURRENCE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034072645     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites. Science 219: 983-985, 1983.
2. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312, 1989.
3. Leung DW, Cachianes G, Kuang W-J, Gocddel DV Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
4. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50: 1774-1778, 1990.
5. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54: 276-280, 1994.
6. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516, 1995.
7. Doldi N, Bassan M, Gulisano M, Broccoli V, Boncinelli E, Ferrari A: Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer. Gynecol Endocrinol 10: 375-382, 1996.
8. Mattern J, Stammler G, Koonagi R, Wallwiener D, Kaufmann M, Volm M: Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res 17: 621-624, 1997.
9. Yeo K-T, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF, Yeo T-K: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53: 2912-2918, 1993.
10. Hong Q, Nagy JA, Senger DR, Dvorak HF, Dvorak AM: Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem 43: 381-389, 1995.
11. Kevil CG, Payne DK, Mirc E, Alexander JS: Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 273: 15099-15103, 1998.
12. 121. Cancer Res 55: 5296-5301, 1995.
13. Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H: An antihuman VEGF monoclonal antibody, MV833, which exhibits potent antitumor activity in vivo. Hybridoma 17: 185-190, 1998.
14. Asano M, Yukita A, Suzuki H: Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Caner Res 90: 93-100, 1999.
15. Maeda O, Terasawa M, Ishikawa T, Oguchi H, Mizuno K, Kawai M, Kikkawa F, Tomoda Y, Hidaka H: A newly synthesized bifunctional inhibitor, W-77, enhances adriamycin activity against human ovarian carcinoma cells. Cancer Res 53: 2051-2056, 1993.
16. Carmichael J, DeGraff WG, Gazder AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated calorimetric assay, Assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
17. Miles AA, Miles EM: Vascular reaction to histamine, histamine-liberator, and leukotaxine in the skin of guinea pigs. J Physiol 118: 228-257, 1952.
18. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patient. Biochim Biophys Acta 1221: 211-214, 1994.
19. Kondo S, Asano M, Suzuki H: Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 194: 1234-1241, 1993.
20. Olson TA, Mohanraj D, Ramakrishnan S: In vivo neutralization of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. Int J Oncol 8: 505-511, 1996.
21. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer. Am J Pathol 153: 1249-1256, 1998.
22. Luo JC, Toyoda M, Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58: 2594-2600, 1998.
23. Kobayashi H, Okada Y, Asahina T, Gotoh J, Terao T: The kallikreinkinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome. J Mol Endocrinol 20: 363-374, 1998.